$4.00
-0.50%
N/A-$0.02
헬스케어
생명공학
NASDAQ
활발히 거래 중
인텐시티 테라퓨틱스(Intensity Therapeutics, Inc.)는 임상 개발 단계에 있는 생명공학 기업으로, 고형 종양 암 치료용 의약품을 발견, 개발, 상용화하는 데 전념하고 있습니다. 이 ...
인텐시티 테라퓨틱스(Intensity Therapeutics, Inc.)는 임상 개발 단계에 있는 생명공학 기업으로, 고형 종양 암 치료용 의약품을 발견, 개발, 상용화하는 데 전념하고 있습니다. 이 ...
C-레벨 임원은 회사의 재무 전략과 혁신을 이끄는 응집된 리더십 팀입니다.
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
| Lewis H. Bender | 창업자, 사장, 최고경영자(CEO) 및 이사회 의장 | USD 1,015,344 | 1959 | Active | |
| Joseph Talamo | 최고재무책임자(CFO) | USD 576,011 | 1969 | Active | |
| John Wesolowski | 회계책임자(Principal Accounting Officer) & 컨트롤러 | USD 329,209 | 1960 | Active | |
| James Ahlers | 기업 재무 담당 전무(Executive Vice President) | USD 75,088 | 1964 | Active |
| Filing Date | Year | Name | Position | Level | Salary | Bonus | Stock Award | Option Award | Incentive | Other | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-30 | 2025 | Lewis H. Bender | President President and Chief Chief Executive Officer | Founder / CEO | $549.15K | $411.86K | $0 | $340.14K | $0 | $54.33K | $1.36M |
| 2026-04-30 | 2025 | Joseph Talamo | Chief Chief Financial Officer | C-Level | $374.70K | $152.44K | $0 | $147.73K | $0 | $48.88K | $723.74K |
| 2026-04-30 | 2025 | John Wesolowski | Principal Principal Accounting Officer and Controller | Other | $246.82K | $74.98K | $0 | $49.24K | $0 | $7.41K | $378.45K |
| 2026-04-30 | 2024 | Lewis H. Bender | President President and Chief Chief Executive Officer | Founder / CEO | $544.12K | $0 | $0 | $1.89M | $0 | $52.89K | $2.49M |
| 2026-04-30 | 2024 | Joseph Talamo | Chief Chief Financial Officer | C-Level | $370.00K | $0 | $0 | $1.25M | $0 | $46.93K | $1.66M |
| 2026-04-30 | 2024 | John Wesolowski | Principal Principal Accounting Officer and Controller | Other | $251.35K | $0 | $0 | $308.23K | $0 | $9.55K | $569.13K |
Sum of disclosed compensation by year (USD million)
Top founder/C-level executives over time (USD million)